嚢胞性線維症市場：薬剤クラス別、投与経路別-2025～2030年の世界予測

嚢胞性線維症市場は、2023年に58億8,000万米ドルと評価され、2024年には64億4,000万米ドルに達すると予測され、CAGR 9.53％で成長し、2030年には111億3,000万米ドルに達すると予測されています。

嚢胞性線維症（CF）は、呼吸器系と消化器系に影響を及ぼす遺伝病であり、CFTR遺伝子の変異により、濃厚で粘着性の粘液が産生されます。CFへの対処の必要性は、患者のQOLや余命に深刻な影響を与えることで強調され、効果的な治療に対する大きな需要を生み出しています。市場の用途は主に、CFの症状を管理・治療するために開発された医薬品、診断薬、医療機器です。最終用途は、主に病院、クリニック、CF患者のための先進的治療法を必要とする専門医療機関です。CF市場に影響を与える主要成長要因としては、診断技術の向上による有病率の増加、製薬会社の研究開発投資の増加、世界の医療インフラの強化などが挙げられます。革新的な遺伝子治療や個別化医療アプローチの開発には潜在的な治療機会があり、CRISPRやmRNA技術の飛躍的進歩により、CFの標的治療への道が開かれつつあります。企業は、研究機関とのパートナーシップに投資し、個別化医療のソリューションを優先することで、こうした機会をつかむことができます。しかし、高額な治療費、厳しい規制の枠組み、新興国市場における認知度の低さといった制約が、市場拡大の課題となっています。また、CFの遺伝学は複雑であるため、変異に特異的な治療法を完全に理解するためには広範な調査が必要であり、新たな治療法の導入ペースが遅くなる可能性があります。技術革新のための最良のセグメントとしては、遺伝子編集技術の進歩、ドラッグデリバリーシステムの改善、希少変異に対応する新規治療法の探求などが挙げられます。詳細な考察により、市場競争は激しいがやりがいのある市場であり、技術の進歩と、改善された利用しやすい治療に対する根強い需要に後押しされていることが明らかになりました。戦略的提携、最先端研究への継続的投資、世界的認知度向上への努力は、市場機会を活用し課題を軽減する上で極めて重要です。

市場力学：急速に進化する嚢胞性線維症市場の主要市場洞察を公開

嚢胞性線維症市場は、需要と供給のダイナミックな相互作用によって変貌を遂げています。このような市場力学の進化を理解することで、企業は十分な情報に基づいた投資決定、戦略的決定の精緻化、そして新たなビジネス機会の獲得に備えることができます。こうした動向を包括的に把握することで、企業は政治的、地理的、技術的、社会的、経済的な領域にわたる様々なリスクを軽減することができるとともに、消費者行動とそれが製造コストや購買動向に与える影響をより明確に理解することができます。

• 市場促進要因
  • 嚢胞性線維症の普及率上昇と診断技術の向上
  • 嚢胞性線維症に対する世界的認知度の向上
  • NGO、政府、非公開会社による積極的な取り組み
• 市場抑制要因
  • 特許切れとジェネリック医薬品
  • 遺伝子変異率の増加
• 市場機会
  • 研究開発活動と強力な医薬品開発パイプライン
  • 戦略的提携、合併、買収の増加
• 市場課題
  • 高額な治療費と複雑な病態生理

ポーターのファイブフォース：嚢胞性線維症市場をナビゲートする戦略ツール

ポーターのファイブフォースフレームワークは、市場情勢の競合情勢を理解するための重要なツールです。ポーターのファイブフォースフレームワークは、企業の競合を評価し、戦略的機会を探るための明確な手法を記載しています。このフレームワークは、企業が市場内の勢力図を評価し、新規事業の収益性を判断するのに役立ちます。これら洞察により、企業は自社の強みを活かし、弱みに対処し、潜在的な課題を回避することができ、より強靭な市場でのポジショニングを確保することができます。

PESTLE分析：嚢胞性線維症市場における外部からの影響の把握

外部マクロ環境要因は、嚢胞性線維症市場の業績力学を形成する上で極めて重要な役割を果たします。政治的、経済的、社会的、技術的、法的、環境的要因の分析は、これらの影響をナビゲートするために必要な情報を記載しています。PESTLE要因を調査することで、企業は潜在的なリスクと機会をよりよく理解することができます。この分析により、企業は規制、消費者の嗜好、経済動向の変化を予測し、先を見越した積極的な意思決定を行う準備ができます。

市場シェア分析：嚢胞性線維症市場における競合情勢の把握

嚢胞性線維症市場の詳細な市場シェア分析により、ベンダーの業績を包括的に評価することができます。企業は、収益、顧客ベース、成長率などの主要指標を比較することで、競争上のポジショニングを明らかにすることができます。この分析により、市場の集中、セグメント化、統合の動向が明らかになり、ベンダーは競争が激化する中で自社の地位を高める戦略的意思決定を行うために必要な知見を得ることができます。

FPNVポジショニングマトリックス：嚢胞性線維症市場におけるベンダーのパフォーマンス評価

FPNVポジショニングマトリックスは、嚢胞性線維症市場においてベンダーを評価するための重要なツールです。このマトリックスにより、ビジネス組織はベンダーのビジネス戦略と製品満足度に基づき評価することで、目標に沿った十分な情報に基づいた意思決定を行うことができます。4つの象限によってベンダーを明確かつ正確にセグメント化し、戦略目標に最適なパートナーやソリューションを特定することができます。

戦略分析と推奨：嚢胞性線維症市場における成功への道筋を描く

嚢胞性線維症市場の戦略分析は、世界市場でのプレゼンス強化を目指す企業にとって不可欠です。主要なリソース、能力、業績指標を見直すことで、企業は成長機会を特定し、改善に取り組むことができます。このアプローチにより、競合情勢における課題を克服し、新たなビジネス機会を活かして長期的な成功を収めるための体制を整えることができます。

本レポートでは、主要な注目セグメントを網羅した市場の包括的な分析を提供しています。

1.市場の浸透度：現在の市場環境の詳細なレビュー、主要企業による広範なデータ、市場でのリーチと全体的な影響力を評価します。

2.市場の開拓度：新興市場における成長機会を特定し、既存セグメントにおける拡大可能性を評価し、将来の成長に向けた戦略的ロードマップを記載しています。

3.市場の多様化：最近の製品発売、未開拓の地域、産業の主要な進歩、市場を形成する戦略的投資を分析します。

4.競合の評価と情報：競合情勢を徹底的に分析し、市場シェア、事業戦略、製品ポートフォリオ、認証、規制当局の承認、特許動向、主要企業の技術進歩などを検証します。

5.製品開発とイノベーション：将来の市場成長を促進すると期待される最先端技術、研究開発活動、製品イノベーションをハイライトしています。

また、利害関係者が十分な情報を得た上で意思決定できるよう、重要な質問にも答えています。

1.現在の市場規模と今後の成長予測は？

2.最高の投資機会を提供する製品、地域はどこか？

3.市場を形成する主要技術動向と規制の影響とは？

4.主要ベンダーの市場シェアと競合ポジションは？

5.ベンダーの市場参入・撤退戦略の原動力となる収益源と戦略的機会は何か？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 嚢胞性線維症の普及率の上昇と診断技術の向上
    • 嚢胞性線維症の世界の認知度の向上
    • NGO、政府、非公開会社による好ましい取り組み
  • 抑制要因
    • 特許切れとジェネリック医薬品
    • 遺伝子変異率の増加
  • 機会
    • 研究開発活動と強力な医薬品開発パイプライン
    • 戦略的コラボレーション、合併、買収の拡大
  • 課題
    • 治療にかかる費用が高く、病態生理が複雑である
• 市場セグメンテーション分析
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治
  • 経済
  • 社会
  • 技術
  • 法律
  • 環境

第6章 嚢胞性線維症市場：薬剤クラス別

• イントロダクション
• 気管支拡大薬
• 嚢胞性線維症治療剤
• 粘液溶解薬
• 膵臓酵素サプリメント

第7章 嚢胞性線維症市場：投与経路別

• イントロダクション
• 吸入薬
• 経口薬

第8章 南北アメリカの嚢胞性線維症市場

• イントロダクション
• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第9章 アジア太平洋の嚢胞性線維症市場

• イントロダクション
• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第10章 欧州・中東・アフリカの嚢胞性線維症市場

• イントロダクション
• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第11章 競合情勢

• 市場シェア分析、2023年
• FPNVポジショニングマトリックス、2023年
• 競合シナリオ分析
• 戦略分析と提言

企業一覧

• AbbVie Inc.
• Alcresta Therapeutics, Inc.
• AlgiPharma AS
• AstraZeneca PLC
• CHIESI Farmaceutici S.p.A.
• Elucigene Diagnostics by Delta Diagnostics (UK) Limited
• F. Hoffmann-La Roche AG
• Galapagos NV
• Gilead Sciences, Inc.
• Johnson & Johnson Services, Inc.
• NovaBIoTics Ltd.
• Novartis AG
• Pharmaxis Ltd.
• PTC Therapeutics, Inc.
• Vertex Pharmaceuticals Incorporated

LIST OF FIGURES

• FIGURE 1. CYSTIC FIBROSIS MARKET RESEARCH PROCESS
• FIGURE 2. CYSTIC FIBROSIS MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL CYSTIC FIBROSIS MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL CYSTIC FIBROSIS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 5. GLOBAL CYSTIC FIBROSIS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. GLOBAL CYSTIC FIBROSIS MARKET SIZE, BY DRUG CLASS, 2023 VS 2030 (%)
• FIGURE 7. GLOBAL CYSTIC FIBROSIS MARKET SIZE, BY DRUG CLASS, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL CYSTIC FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL CYSTIC FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. AMERICAS CYSTIC FIBROSIS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 11. AMERICAS CYSTIC FIBROSIS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. UNITED STATES CYSTIC FIBROSIS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 13. UNITED STATES CYSTIC FIBROSIS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. ASIA-PACIFIC CYSTIC FIBROSIS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 15. ASIA-PACIFIC CYSTIC FIBROSIS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. EUROPE, MIDDLE EAST & AFRICA CYSTIC FIBROSIS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 17. EUROPE, MIDDLE EAST & AFRICA CYSTIC FIBROSIS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 18. CYSTIC FIBROSIS MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 19. CYSTIC FIBROSIS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. CYSTIC FIBROSIS MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL CYSTIC FIBROSIS MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL CYSTIC FIBROSIS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL CYSTIC FIBROSIS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. CYSTIC FIBROSIS MARKET DYNAMICS
• TABLE 7. GLOBAL CYSTIC FIBROSIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL CYSTIC FIBROSIS MARKET SIZE, BY BRONCHODILATORS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL CYSTIC FIBROSIS MARKET SIZE, BY CFTR MODULATORS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL CYSTIC FIBROSIS MARKET SIZE, BY MUCOLYTICS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL CYSTIC FIBROSIS MARKET SIZE, BY PANCREATIC ENZYME SUPPLEMENTS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL CYSTIC FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL CYSTIC FIBROSIS MARKET SIZE, BY INHALED DRUGS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL CYSTIC FIBROSIS MARKET SIZE, BY ORAL DRUGS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 15. AMERICAS CYSTIC FIBROSIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 16. AMERICAS CYSTIC FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 17. AMERICAS CYSTIC FIBROSIS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 18. ARGENTINA CYSTIC FIBROSIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 19. ARGENTINA CYSTIC FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 20. BRAZIL CYSTIC FIBROSIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 21. BRAZIL CYSTIC FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 22. CANADA CYSTIC FIBROSIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 23. CANADA CYSTIC FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 24. MEXICO CYSTIC FIBROSIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 25. MEXICO CYSTIC FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 26. UNITED STATES CYSTIC FIBROSIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 27. UNITED STATES CYSTIC FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 28. UNITED STATES CYSTIC FIBROSIS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 29. ASIA-PACIFIC CYSTIC FIBROSIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 30. ASIA-PACIFIC CYSTIC FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 31. ASIA-PACIFIC CYSTIC FIBROSIS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 32. AUSTRALIA CYSTIC FIBROSIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 33. AUSTRALIA CYSTIC FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 34. CHINA CYSTIC FIBROSIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 35. CHINA CYSTIC FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 36. INDIA CYSTIC FIBROSIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 37. INDIA CYSTIC FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 38. INDONESIA CYSTIC FIBROSIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 39. INDONESIA CYSTIC FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 40. JAPAN CYSTIC FIBROSIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 41. JAPAN CYSTIC FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 42. MALAYSIA CYSTIC FIBROSIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 43. MALAYSIA CYSTIC FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 44. PHILIPPINES CYSTIC FIBROSIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 45. PHILIPPINES CYSTIC FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 46. SINGAPORE CYSTIC FIBROSIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 47. SINGAPORE CYSTIC FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 48. SOUTH KOREA CYSTIC FIBROSIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 49. SOUTH KOREA CYSTIC FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 50. TAIWAN CYSTIC FIBROSIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 51. TAIWAN CYSTIC FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 52. THAILAND CYSTIC FIBROSIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 53. THAILAND CYSTIC FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 54. VIETNAM CYSTIC FIBROSIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 55. VIETNAM CYSTIC FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 56. EUROPE, MIDDLE EAST & AFRICA CYSTIC FIBROSIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 57. EUROPE, MIDDLE EAST & AFRICA CYSTIC FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 58. EUROPE, MIDDLE EAST & AFRICA CYSTIC FIBROSIS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 59. DENMARK CYSTIC FIBROSIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 60. DENMARK CYSTIC FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 61. EGYPT CYSTIC FIBROSIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 62. EGYPT CYSTIC FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 63. FINLAND CYSTIC FIBROSIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 64. FINLAND CYSTIC FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 65. FRANCE CYSTIC FIBROSIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 66. FRANCE CYSTIC FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 67. GERMANY CYSTIC FIBROSIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 68. GERMANY CYSTIC FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 69. ISRAEL CYSTIC FIBROSIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 70. ISRAEL CYSTIC FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 71. ITALY CYSTIC FIBROSIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 72. ITALY CYSTIC FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 73. NETHERLANDS CYSTIC FIBROSIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 74. NETHERLANDS CYSTIC FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 75. NIGERIA CYSTIC FIBROSIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 76. NIGERIA CYSTIC FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 77. NORWAY CYSTIC FIBROSIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 78. NORWAY CYSTIC FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 79. POLAND CYSTIC FIBROSIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 80. POLAND CYSTIC FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 81. QATAR CYSTIC FIBROSIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 82. QATAR CYSTIC FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 83. RUSSIA CYSTIC FIBROSIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 84. RUSSIA CYSTIC FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 85. SAUDI ARABIA CYSTIC FIBROSIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 86. SAUDI ARABIA CYSTIC FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 87. SOUTH AFRICA CYSTIC FIBROSIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 88. SOUTH AFRICA CYSTIC FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 89. SPAIN CYSTIC FIBROSIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 90. SPAIN CYSTIC FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 91. SWEDEN CYSTIC FIBROSIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 92. SWEDEN CYSTIC FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 93. SWITZERLAND CYSTIC FIBROSIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 94. SWITZERLAND CYSTIC FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 95. TURKEY CYSTIC FIBROSIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 96. TURKEY CYSTIC FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 97. UNITED ARAB EMIRATES CYSTIC FIBROSIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 98. UNITED ARAB EMIRATES CYSTIC FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 99. UNITED KINGDOM CYSTIC FIBROSIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 100. UNITED KINGDOM CYSTIC FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 101. CYSTIC FIBROSIS MARKET SHARE, BY KEY PLAYER, 2023
• TABLE 102. CYSTIC FIBROSIS MARKET, FPNV POSITIONING MATRIX, 2023

The Cystic Fibrosis Market was valued at USD 5.88 billion in 2023, expected to reach USD 6.44 billion in 2024, and is projected to grow at a CAGR of 9.53%, to USD 11.13 billion by 2030.

Cystic Fibrosis (CF) is a genetic disorder that affects the respiratory and digestive systems, caused by mutations in the CFTR gene leading to the production of thick, sticky mucus. The necessity of addressing CF is underscored by its severe impact on patients' quality of life and life expectancy, creating a substantial demand for effective treatments. The market's application primarily lies within pharmaceuticals, diagnostics, and medical devices developed to manage and treat the symptoms of CF. End-use scopes are mainly hospitals, clinics, and specialty healthcare institutions that require advanced treatment options for CF patients. Key growth factors influencing the CF market include increasing prevalence due to improved diagnostic techniques, rising investments in research and development from pharmaceutical companies, and enhanced healthcare infrastructure globally. Potential opportunities lie in the development of innovative gene therapies and personalized medicine approaches, with breakthroughs in CRISPR and mRNA technology paving the way for targeted CF treatments. Companies can grab these opportunities by investing in partnerships with research institutions and prioritizing personalized healthcare solutions. However, limitations such as high treatment costs, stringent regulatory frameworks, and inadequate awareness in developing regions pose challenges to market expansion. The complexity of CF genetics also necessitates extensive research to fully comprehend mutation-specific therapies, potentially slowing the pace of new treatment introductions. Best areas for innovation include advancing gene editing technologies, improving drug delivery systems, and exploring novel therapeutics that address rare mutations. Detailed insights reveal a competitive yet rewarding market nature, driven by technological advances and a persistent demand for improved, accessible treatments. Strategic collaborations, continuous investment in cutting-edge research, and efforts to enhance global awareness are crucial for capitalizing on market opportunities and mitigating challenges.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Cystic Fibrosis Market

The Cystic Fibrosis Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Rising prevalence of Cystic Fibrosis & improved diagnostic technologies
  • Increasing global awareness for Cystic Fibrosis
  • Favorable initiatives are taken by NGOs, government, and private companies
• Market Restraints
  • Expiring patents and generic drugs
  • Increase in genetic mutation rate
• Market Opportunities
  • Research & development activities and robust drug development pipeline
  • Growing strategic collaborations, merger, and acquisition
• Market Challenges
  • High cost involved in treatment and complicated pathophysiology

Porter's Five Forces: A Strategic Tool for Navigating the Cystic Fibrosis Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Cystic Fibrosis Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Cystic Fibrosis Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Cystic Fibrosis Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Cystic Fibrosis Market

A detailed market share analysis in the Cystic Fibrosis Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Cystic Fibrosis Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Cystic Fibrosis Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Cystic Fibrosis Market

A strategic analysis of the Cystic Fibrosis Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Cystic Fibrosis Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Alcresta Therapeutics, Inc., AlgiPharma AS, AstraZeneca PLC, CHIESI Farmaceutici S.p.A., Elucigene Diagnostics by Delta Diagnostics (UK) Limited, F. Hoffmann-La Roche AG, Galapagos NV, Gilead Sciences, Inc., Johnson & Johnson Services, Inc., NovaBiotics Ltd., Novartis AG, Pharmaxis Ltd., PTC Therapeutics, Inc., and Vertex Pharmaceuticals Incorporated.

Market Segmentation & Coverage

This research report categorizes the Cystic Fibrosis Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Drug Class, market is studied across Bronchodilators, CFTR Modulators, Mucolytics, and Pancreatic Enzyme Supplements.
• Based on Route of Administration, market is studied across Inhaled Drugs and Oral Drugs.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Rising prevalence of Cystic Fibrosis & improved diagnostic technologies
    • 5.1.1.2. Increasing global awareness for Cystic Fibrosis
    • 5.1.1.3. Favorable initiatives are taken by NGOs, government, and private companies
  • 5.1.2. Restraints
    • 5.1.2.1. Expiring patents and generic drugs
    • 5.1.2.2. Increase in genetic mutation rate
  • 5.1.3. Opportunities
    • 5.1.3.1. Research & development activities and robust drug development pipeline
    • 5.1.3.2. Growing strategic collaborations, merger, and acquisition
  • 5.1.4. Challenges
    • 5.1.4.1. High cost involved in treatment and complicated pathophysiology
• 5.2. Market Segmentation Analysis
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Cystic Fibrosis Market, by Drug Class

• 6.1. Introduction
• 6.2. Bronchodilators
• 6.3. CFTR Modulators
• 6.4. Mucolytics
• 6.5. Pancreatic Enzyme Supplements

7. Cystic Fibrosis Market, by Route of Administration

• 7.1. Introduction
• 7.2. Inhaled Drugs
• 7.3. Oral Drugs

8. Americas Cystic Fibrosis Market

• 8.1. Introduction
• 8.2. Argentina
• 8.3. Brazil
• 8.4. Canada
• 8.5. Mexico
• 8.6. United States

9. Asia-Pacific Cystic Fibrosis Market

• 9.1. Introduction
• 9.2. Australia
• 9.3. China
• 9.4. India
• 9.5. Indonesia
• 9.6. Japan
• 9.7. Malaysia
• 9.8. Philippines
• 9.9. Singapore
• 9.10. South Korea
• 9.11. Taiwan
• 9.12. Thailand
• 9.13. Vietnam

10. Europe, Middle East & Africa Cystic Fibrosis Market

• 10.1. Introduction
• 10.2. Denmark
• 10.3. Egypt
• 10.4. Finland
• 10.5. France
• 10.6. Germany
• 10.7. Israel
• 10.8. Italy
• 10.9. Netherlands
• 10.10. Nigeria
• 10.11. Norway
• 10.12. Poland
• 10.13. Qatar
• 10.14. Russia
• 10.15. Saudi Arabia
• 10.16. South Africa
• 10.17. Spain
• 10.18. Sweden
• 10.19. Switzerland
• 10.20. Turkey
• 10.21. United Arab Emirates
• 10.22. United Kingdom

11. Competitive Landscape

• 11.1. Market Share Analysis, 2023
• 11.2. FPNV Positioning Matrix, 2023
• 11.3. Competitive Scenario Analysis
• 11.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. AbbVie Inc.
• 2. Alcresta Therapeutics, Inc.
• 3. AlgiPharma AS
• 4. AstraZeneca PLC
• 5. CHIESI Farmaceutici S.p.A.
• 6. Elucigene Diagnostics by Delta Diagnostics (UK) Limited
• 7. F. Hoffmann-La Roche AG
• 8. Galapagos NV
• 9. Gilead Sciences, Inc.
• 10. Johnson & Johnson Services, Inc.
• 11. NovaBiotics Ltd.
• 12. Novartis AG
• 13. Pharmaxis Ltd.
• 14. PTC Therapeutics, Inc.
• 15. Vertex Pharmaceuticals Incorporated